JP2023542312A5 - - Google Patents
Info
- Publication number
- JP2023542312A5 JP2023542312A5 JP2023516810A JP2023516810A JP2023542312A5 JP 2023542312 A5 JP2023542312 A5 JP 2023542312A5 JP 2023516810 A JP2023516810 A JP 2023516810A JP 2023516810 A JP2023516810 A JP 2023516810A JP 2023542312 A5 JP2023542312 A5 JP 2023542312A5
- Authority
- JP
- Japan
- Prior art keywords
- transmembrane
- domain
- nucleic acid
- fusion protein
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063077658P | 2020-09-13 | 2020-09-13 | |
| US63/077,658 | 2020-09-13 | ||
| US202163144945P | 2021-02-02 | 2021-02-02 | |
| US63/144,945 | 2021-02-02 | ||
| US202163173476P | 2021-04-11 | 2021-04-11 | |
| US63/173,476 | 2021-04-11 | ||
| PCT/CN2021/117886 WO2022053036A1 (en) | 2020-09-13 | 2021-09-13 | Downregulation of membrane-bound proteins by receptor tac technology |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542312A JP2023542312A (ja) | 2023-10-06 |
| JP2023542312A5 true JP2023542312A5 (cg-RX-API-DMAC7.html) | 2024-06-26 |
| JP7685044B2 JP7685044B2 (ja) | 2025-05-28 |
Family
ID=80629753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516810A Active JP7685044B2 (ja) | 2020-09-13 | 2021-09-13 | 受容体tac技術による膜結合タンパク質の下方制御 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230355764A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4178986B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7685044B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116368152A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022053036A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | 1型糖尿病を予防するための方法および組成物 |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| KR20240004937A (ko) | 2021-05-05 | 2024-01-11 | 이매틱스 바이오테크놀로지스 게엠베하 | Bma031 항원 결합 폴리펩타이드 |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| EP4565333A4 (en) * | 2022-08-04 | 2026-07-22 | Univ Michigan | GRAIL-1 PEPTIDE-BASED PRODUCTS AND METHODS |
| CN116063579B (zh) * | 2022-11-17 | 2026-02-27 | 安徽医科大学 | 一种靶向人cd47的嵌合抗原受体、表达嵌合抗原受体的巨噬细胞及其应用 |
| WO2024168276A2 (en) * | 2023-02-09 | 2024-08-15 | Cargo Therapeutics, Inc. | Compositions and methods for immunotherapies |
| WO2025011459A1 (en) * | 2023-07-07 | 2025-01-16 | Nanjing Legend Biotech Co., Ltd. | Proteins and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2931898E (pt) * | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| CA2994969A1 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Ltd | Protein-based t-cell receptor knockdown |
| US20200087681A1 (en) * | 2016-12-21 | 2020-03-19 | Ucl Business Plc | Therapeutic cells |
| CN110753693A (zh) * | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| GB201710620D0 (en) | 2017-07-03 | 2017-08-16 | Glaxosmithkline Intellectual Property Ltd | Targeted protein degradation |
| CA3071282A1 (en) * | 2017-08-10 | 2019-02-14 | National University Of Singapore | T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof |
| WO2019089592A1 (en) * | 2017-10-31 | 2019-05-09 | The General Hospital Corporation | Molecular switch-mediated control of engineered cells |
| JP2021515582A (ja) * | 2018-03-16 | 2021-06-24 | コーネル・ユニバーシティーCornell University | 操作された細菌ユビキチンリガーゼ模倣物を用いる、幅広い範囲にわたるプロテオーム編集 |
| WO2020146250A1 (en) * | 2019-01-07 | 2020-07-16 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS |
| US20220133792A1 (en) * | 2019-02-01 | 2022-05-05 | The Trustees Of Dartmouth College | Signaling platforms for chimeric antigen receptor t cells |
| CN113088495B (zh) * | 2020-01-09 | 2024-08-16 | 苏州方德门达新药开发有限公司 | 工程改造的t细胞、其制备及应用 |
-
2021
- 2021-09-13 US US18/026,063 patent/US20230355764A1/en active Pending
- 2021-09-13 CN CN202180062485.5A patent/CN116368152A/zh active Pending
- 2021-09-13 WO PCT/CN2021/117886 patent/WO2022053036A1/en not_active Ceased
- 2021-09-13 EP EP21866088.4A patent/EP4178986B1/en active Active
- 2021-09-13 JP JP2023516810A patent/JP7685044B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hutchings et al. | Opportunities for therapeutic antibodies directed at G-protein-coupled receptors | |
| JP7822587B2 (ja) | ヘテロ二量体化Igドメイン | |
| JP2025138715A5 (cg-RX-API-DMAC7.html) | ||
| JP2024023228A5 (cg-RX-API-DMAC7.html) | ||
| Lebbink et al. | The soluble leukocyte-associated Ig-like receptor (LAIR)-2 antagonizes the collagen/LAIR-1 inhibitory immune interaction | |
| JP6025502B2 (ja) | B細胞関連疾患を処置するための二重特異性抗cd3、抗cd19抗体構築物を含む薬学的組成物 | |
| JP6101638B2 (ja) | 多価ヘテロマルチマー足場設計及び構築物 | |
| JP2020517294A5 (cg-RX-API-DMAC7.html) | ||
| JP2025142045A5 (cg-RX-API-DMAC7.html) | ||
| JP2023518134A5 (cg-RX-API-DMAC7.html) | ||
| JP2022505663A5 (cg-RX-API-DMAC7.html) | ||
| US20200157178A1 (en) | Chimeric antigen receptors specific to avb6 integrin and methods of use thereof to treat cancer | |
| CA2956126A1 (en) | Sirp-alpha immunoglobulin fusion proteins | |
| JP2020511949A5 (cg-RX-API-DMAC7.html) | ||
| JP2023549116A (ja) | 選択性が増大した多標的二重特異性抗原結合分子 | |
| Rao et al. | Mechanism of homophilic binding mediated by the neural cell adhesion molecule NCAM. Evidence for isologous interaction. | |
| CA2430528A1 (en) | Hybrid antibodies | |
| JP2012514997A (ja) | 組換え一価抗体 | |
| JP2024504728A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2015146438A1 (ja) | ヒト上皮増殖因子受容体を標的とした二重特異性抗体 | |
| EP3590578A1 (en) | Muscarinic acetylcholine receptor binding agents and uses thereof | |
| US20030138440A1 (en) | Multimeric proteins and methods of making and using same | |
| JP2024515919A5 (cg-RX-API-DMAC7.html) | ||
| CN119137147A (zh) | 具有增加的选择性的多链多靶向性双特异性抗原结合分子 | |
| JP2023527908A (ja) | 4-1bbをターゲティングする多量体免疫調節物質 |